Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24702664 | 0.86 | TDP1 (0.56) | TDP1L3MBTL1KDM4ELMNAALDH1A1 | |
| SCHEMBL1102422 | 0.85 | TDP1 (0.55) | TDP1L3MBTL1KDM4ELMNAALDH1A1 | |
| SCHEMBL29405271 | 0.81 | MAPK14 (0.81) | MAPK14MAPK10ADORA2ATDP1L3MBTL1 | |
| SCHEMBL71619 | 0.81 | MAPK14 (0.81) | MAPK14MAPK10ADORA2ATDP1L3MBTL1 | |
| SCHEMBL8020858 | 0.81 | MAPK14 (0.54) | MAPK14MAPK10TDP1KDM4EALDH1A1 | |
| SCHEMBL23776022 | 0.81 | SRC (0.42) | MAPK14MAPK10ADORA2ATDP1L3MBTL1 | |
| SCHEMBL13787414 | 0.80 | KDM4E (0.68) | ADORA2ATDP1L3MBTL1KDM4ELMNA | |
| SCHEMBL13787410 | 0.80 | AKT1 (0.51) | ADORA2ATDP1L3MBTL1KDM4ELMNA | |
| SCHEMBL714455 | 0.79 | TDP1 (0.41) | MAPK14MAPK10TDP1L3MBTL1KDM4E | |
| SCHEMBL29767839 | 0.79 | MAPK14 (0.78) | MAPK14MAPK10ADORA2ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962551-B2 | Quinoxalinyl derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| WO-2009073719-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | SQOR, ATG4A, NQO1 | MAPK14 3221/4885MAPK10 3496/4885ADORA2A 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.